metformin + enalapril + simvastatin

This is a combination of three small molecule drugs—metformin, enalapril, and simvastatin—used together for the management of patients with comorbid type 2 diabetes mellitus, hypertension, and hyperlipidemia. - **Metformin** is a biguanide antihyperglycemic agent that improves glycemic control by decreasing hepatic glucose production and increasing insulin sensitivity[1]. - **Enalapril** is an angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension and heart failure by inhibiting the conversion of angiotensin I to angiotensin II, leading to vasodilation. - **Simvastatin** is an HMG-CoA reductase inhibitor (statin) that lowers cholesterol levels by inhibiting endogenous cholesterol synthesis in the liver[6]. The combination targets multiple cardiovascular risk factors simultaneously. While this specific triple-drug formulation does not have a unique brand name or fixed-dose product widely available on the market as of now, these agents are commonly co-prescribed in clinical practice for patients at high risk for cardiovascular events due to diabetes and dyslipidemia[2].

Other names

Poly-pill (metformin, enalapril, simvastatin)PPCVD poly-pill